Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 32, 2011, Pages 4224-4226

  Domchek, Susan M ^a   Mitchell, Gillian ^b   Lindeman, Geoffrey J ^c   Tung, Nadine M ^d   Balmaña, Judith ^e   Isakoff, Steven J ^f   Schmutzler, Rita ^g   Audeh, M William ^h   Loman, Niklas ⁱ   Scott, Clare ^c   Friedlander, Michael ^j   Kaufman, Bella ^k   Garber, Judy E ^l   Tutt, Andrew ^m   Robson, Mark E ⁿ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF COLOGNE   (Germany)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j The Prince of Wales Cancer Centre   (Australia)

^k SHEBA MEDICAL CENTER   (Israel)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m KING'S COLLEGE LONDON   (United Kingdom)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CEP 9722; CETUXIMAB; CRIZOTINIB; CYTOTOXIC AGENT; DASATINIB; DOUBLE STRANDED DNA; ERLOTINIB; FULVESTRANT; IMATINIB; LAPATINIB; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NILOTINIB; OLAPARIB; PF 01367338; PF 0137338; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VELIPARIB; VEMURAFENIB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL DEATH; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DNA DAMAGE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXCISION REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE TARGETING; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULAR THERAPY; NOTE; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; POLY(ADP-RIBOSE) POLYMERASES; RESEARCH DESIGN;

EID: 81155151836     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.8134     Document Type: Note

References (14)

1. Thompson D, Easton DF, Breast Cancer Linkage Consortium: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002 (Pubitemid 35154140)
2. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers: The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316, 1999
3. Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005 (Pubitemid 40559006)
4. Bryant HE, Schultz N, Thomas HD, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005 (Pubitemid 40559005)
5. Fong PC, Boss DS, Yap TA, et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
6. Tutt A, Robson M, Garber JE, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244, 2010
7. Audeh MW, Carmichael J, Penson RT, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376:245-251, 2010
8. Isakoff SJ, Overmoyer B, Tung NM, et al.: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28:118s 2010 (suppl; abstr 1019)
9. Sandhu SK, Wenham RM, Wilding G, et al.: First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol 28:233s, 2010 (suppl; abstr 3001)
10. Gelmon KA, Hirte HW, Robidoux A, et al.: Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 28:233s, 2010 (suppl; abstr 3002)
11. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004 (Pubitemid 39331153)
12. Alli E, Sharma VB, Sunderesakumar P, et al.: Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69:3589-3596, 2009
13. O'Shaughnessy J, Osborne C, Pippen JE, et al.: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214, 2011
14. O'Shaughnessy J: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer. J Clin Oncol 29:81s, 2011 (suppl; abstr 1007)